sulfasalazine has been researched along with Genetic Predisposition in 14 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Progression of radiographic damage and association of radiographic damage and genetic predisposition were compared in two cohorts, one treated according to the delayed treatment strategy (initial treatment with analgesics), the other treated according to the early treatment strategy (treatment with disease modifying antirheumatic drugs (DMARDs) chloroquine or sulfasalazine)." | 5.11 | Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. ( Breedveld, FC; Hazes, JM; Huizinga, TW; Lard, LR; le Cessie, S; van Aken, J, 2004) |
| "Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs." | 1.48 | NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. ( Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018) |
| " The aim of the present study was to investigate associations of the genotypes of NAT2 with inflammatory bowel disease (IBD), and with adverse effects of SASP, which is used as the first-line treatment of IBD." | 1.34 | N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. ( Chen, B; Chen, M; Guo, Q; Hu, Z; Li, J; Xia, B; Ye, M, 2007) |
| "Thirty-nine patients reacted with agranulocytosis, while 75 patients had been treated for a minimum of 3 months without haematological side-effects." | 1.31 | Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. ( Rane, A; Stjernberg, E; Wadelius, M; Wiholm, BE, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, R | 1 |
| Ozeki, T | 1 |
| Hirayama, N | 1 |
| Sekine, A | 1 |
| Yamashita, T | 1 |
| Mashimo, Y | 1 |
| Mizukawa, Y | 1 |
| Shiohara, T | 1 |
| Watanabe, H | 1 |
| Sueki, H | 1 |
| Ogawa, K | 1 |
| Asada, H | 1 |
| Kaniwa, N | 1 |
| Tsukagoshi, E | 1 |
| Matsunaga, K | 1 |
| Niihara, H | 1 |
| Yamaguchi, Y | 1 |
| Aihara, M | 1 |
| Mushiroda, T | 1 |
| Saito, Y | 1 |
| Morita, E | 1 |
| Wu, X | 1 |
| Yang, F | 3 |
| Chen, S | 1 |
| Xiong, H | 1 |
| Zhu, Q | 3 |
| Gao, X | 1 |
| Xing, Q | 3 |
| Luo, X | 3 |
| Kakuta, Y | 1 |
| Kawai, Y | 1 |
| Okamoto, D | 1 |
| Takagawa, T | 1 |
| Ikeya, K | 1 |
| Sakuraba, H | 1 |
| Nishida, A | 1 |
| Nakagawa, S | 1 |
| Miura, M | 1 |
| Toyonaga, T | 1 |
| Onodera, K | 1 |
| Shinozaki, M | 1 |
| Ishiguro, Y | 1 |
| Mizuno, S | 1 |
| Takahara, M | 1 |
| Yanai, S | 1 |
| Hokari, R | 1 |
| Nakagawa, T | 1 |
| Araki, H | 1 |
| Motoya, S | 1 |
| Naito, T | 1 |
| Moroi, R | 1 |
| Shiga, H | 1 |
| Endo, K | 1 |
| Kobayashi, T | 1 |
| Naganuma, M | 1 |
| Hiraoka, S | 1 |
| Matsumoto, T | 1 |
| Nakamura, S | 1 |
| Nakase, H | 1 |
| Hisamatsu, T | 1 |
| Sasaki, M | 1 |
| Hanai, H | 1 |
| Andoh, A | 1 |
| Nagasaki, M | 1 |
| Kinouchi, Y | 1 |
| Shimosegawa, T | 1 |
| Masamune, A | 1 |
| Suzuki, Y | 1 |
| Gu, B | 1 |
| Zhang, L | 1 |
| Xuan, J | 1 |
| Luo, H | 1 |
| Zhou, P | 1 |
| Yan, S | 2 |
| Chen, SA | 2 |
| Cao, Z | 1 |
| Xu, J | 2 |
| Yang, Y | 1 |
| Fu, X | 1 |
| Meng, C | 1 |
| Ma, L | 1 |
| Sun, X | 1 |
| Yamamoto-Furusho, JK | 1 |
| Akar, S | 1 |
| Birlik, M | 1 |
| Sari, I | 1 |
| Onen, F | 1 |
| Akkoc, N | 1 |
| Gültepe, M | 1 |
| Ozcan, O | 1 |
| Ipçioğlu, OM | 1 |
| Kiralp, MZ | 1 |
| Ozçakar, L | 1 |
| Nagy, ZB | 1 |
| Csanád, M | 1 |
| Tóth, K | 1 |
| Börzsönyi, B | 1 |
| Demendi, C | 1 |
| Rigó, J | 1 |
| Joó, JG | 1 |
| van Aken, J | 1 |
| Lard, LR | 1 |
| le Cessie, S | 1 |
| Hazes, JM | 1 |
| Breedveld, FC | 1 |
| Huizinga, TW | 1 |
| Chen, M | 1 |
| Xia, B | 1 |
| Chen, B | 1 |
| Guo, Q | 1 |
| Li, J | 1 |
| Ye, M | 1 |
| Hu, Z | 1 |
| Ranganathan, P | 1 |
| Soejima, M | 1 |
| Kawaguchi, Y | 1 |
| Hara, M | 1 |
| Kamatani, N | 1 |
| Wadelius, M | 1 |
| Stjernberg, E | 1 |
| Wiholm, BE | 1 |
| Rane, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis[NCT01783119] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulfasalazine and Genetic Predisposition
| Article | Year |
|---|---|
Pharmacogenomics in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Biotransformation; Genetic Predisposition | 2008 |
1 trial available for sulfasalazine and Genetic Predisposition
| Article | Year |
|---|---|
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Disease Progression; Epitopes | 2004 |
12 other studies available for sulfasalazine and Genetic Predisposition
| Article | Year |
|---|---|
Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients.
Topics: Adult; Drug Hypersensitivity Syndrome; Female; Genetic Predisposition to Disease; HLA-A11 Antigen; H | 2020 |
Clinical, Viral and Genetic Characteristics of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Allopurinol; Carbamazepine; China; DNA, Vir | 2018 |
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Topics: Alopecia; Antibodies, Monoclonal; Azathioprine; Biomarkers, Pharmacological; Genetic Predisposition | 2018 |
HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population.
Topics: Adult; Alleles; Asian People; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Eosin | 2014 |
Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans.
Topics: Allopurinol; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvul | 2015 |
Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006).
Topics: Adult; Age of Onset; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Co | 2009 |
M694V mutation may have a role in susceptibility to ankylosing spondylitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diclofenac; Drug Combinations; Female; F | 2009 |
Sacroiliitis and muscle cramps in a healthy young man: some spearhead on MTHFR mutations.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Biomarkers; DNA Mutational Analysis; Gene | 2010 |
Current concepts in the genetic diagnostics of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Genetic Predisposition to Disease; HLA-DR | 2010 |
N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Topics: Acetylation; Acetyltransferases; Adolescent; Adult; Aged; Alleles; Anti-Inflammatory Agents, Non-Ste | 2007 |
Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arylamine N-Acetyltransferase; Female; Gen | 2008 |
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Alleles; Anti-Inflammatory | 2000 |